Nature Communications (Jul 2018)
FABP4 as a key determinant of metastatic potential of ovarian cancer
- Kshipra M. Gharpure,
- Sunila Pradeep,
- Marta Sans,
- Rajesha Rupaimoole,
- Cristina Ivan,
- Sherry Y. Wu,
- Emine Bayraktar,
- Archana S. Nagaraja,
- Lingegowda S. Mangala,
- Xinna Zhang,
- Monika Haemmerle,
- Wei Hu,
- Cristian Rodriguez-Aguayo,
- Michael McGuire,
- Celia Sze Ling Mak,
- Xiuhui Chen,
- Michelle A. Tran,
- Alejandro Villar-Prados,
- Guillermo Armaiz Pena,
- Ragini Kondetimmanahalli,
- Ryan Nini,
- Pranavi Koppula,
- Prahlad Ram,
- Jinsong Liu,
- Gabriel Lopez-Berestein,
- Keith Baggerly,
- Livia S. Eberlin,
- Anil K. Sood
Affiliations
- Kshipra M. Gharpure
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Sunila Pradeep
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Marta Sans
- Department of Chemistry, The University of Texas at Austin
- Rajesha Rupaimoole
- Department of Pathology and Institute of RNA Medicine, Beth Israel Deaconess Medical Center Cancer Center, Harvard Medical School
- Cristina Ivan
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center
- Sherry Y. Wu
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Emine Bayraktar
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Archana S. Nagaraja
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Lingegowda S. Mangala
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Xinna Zhang
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center
- Monika Haemmerle
- Martin-Luther-University Halle-Wittenberg, Institute of Pathology
- Wei Hu
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Cristian Rodriguez-Aguayo
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center
- Michael McGuire
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Celia Sze Ling Mak
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Xiuhui Chen
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Michelle A. Tran
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Alejandro Villar-Prados
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- Guillermo Armaiz Pena
- Department of Pharmacology, Ponce Health Sciences University
- Ragini Kondetimmanahalli
- The University of Texas at Austin
- Ryan Nini
- Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center
- Pranavi Koppula
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Prahlad Ram
- Department of Systems Biology, The University of Texas MD Anderson Cancer Center
- Jinsong Liu
- Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center
- Gabriel Lopez-Berestein
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center
- Keith Baggerly
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
- Livia S. Eberlin
- Department of Chemistry, The University of Texas at Austin
- Anil K. Sood
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-018-04987-y
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 14
Abstract
In ovarian cancer, metastatic phenotype may impact surgical outcomes. Here, the authors show miR-409-3p regulates FABP4 which can increase metastatic potential of ovarian cancer, and treatment with DOPC nanoliposomes containing either miR-409--3p mimic or FABP4 siRNA inhibits tumor progression in mice.
